Asset Details
Do you wish to reserve the book?
Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples
Do you wish to request the book?
Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples
2021
Overview
In this work, a surface plasmon resonance (SPR)-based assay for the quantification of antineoplastic drug irinotecan in human plasma samples has been developed for the first time. The selective binding of irinotecan with an aptamer receptor, operating in human plasma, allowed to set-up a novel analytical methodology to detect the drug in the analytical range of interest by using SPR as detection technique. After hybridizing the aptamer to the sensing platform and optimizing the sample preparation procedure, a quantitative assay was validated according to FDA regulatory guidelines. The analytical working range was found between 100 and 7500 ng mL−1 with negligible interferences from plasma components and co-medication associated with the administration of irinotecan. The utility of the new SPR assay was confirmed by analyzing plasma samples in parallel with LC-MS as reference technique, providing a new analytical tool for the therapeutic drug monitoring of irinotecan in patients under chemotherapy regimens.
Publisher
Springer Nature B.V
We currently cannot retrieve any items related to this title. Kindly check back at a later time.